Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen.

Ekaterina Alekseeva, Irina Sominskaya, Dace Skrastina, Irina Egorova, Elizaveta Starodubova, Eriks Kushners, Marija Mihailova, Natalia Petrakova, Ruta Bruvere, Tatyana Kozlovskaya, Maria Isaguliants, Paul Pumpens
{"title":"Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen.","authors":"Ekaterina Alekseeva,&nbsp;Irina Sominskaya,&nbsp;Dace Skrastina,&nbsp;Irina Egorova,&nbsp;Elizaveta Starodubova,&nbsp;Eriks Kushners,&nbsp;Marija Mihailova,&nbsp;Natalia Petrakova,&nbsp;Ruta Bruvere,&nbsp;Tatyana Kozlovskaya,&nbsp;Maria Isaguliants,&nbsp;Paul Pumpens","doi":"10.1186/1479-0556-7-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hepatitis C core protein is an attractive target for HCV vaccine aimed to exterminate HCV infected cells. However, although highly immunogenic in natural infection, core appears to have low immunogenicity in experimental settings. We aimed to design an HCV vaccine prototype based on core, and devise immunization regimens that would lead to potent anti-core immune responses which circumvent the immunogenicity limitations earlier observed.</p><p><strong>Methods: </strong>Plasmids encoding core with no translation initiation signal (pCMVcore); with Kozak sequence (pCMVcoreKozak); and with HCV IRES (pCMVcoreIRES) were designed and expressed in a variety of eukaryotic cells. Polyproteins corresponding to HCV 1b amino acids (aa) 1-98 and 1-173 were expressed in E. coli. C57BL/6 mice were immunized with four 25-microg doses of pCMVcoreKozak, or pCMV (I). BALB/c mice were immunized with 100 microg of either pCMVcore, or pCMVcoreKozak, or pCMVcoreIRES, or empty pCMV (II). Lastly, BALB/c mice were immunized with 20 microg of core aa 1-98 in prime and boost, or with 100 microg of pCMVcoreKozak in prime and 20 microg of core aa 1-98 in boost (III). Antibody response, [3H]-T-incorporation, and cytokine secretion by core/core peptide-stimulated splenocytes were assessed after each immunization.</p><p><strong>Results: </strong>Plasmids differed in core-expression capacity: mouse fibroblasts transfected with pCMVcore, pCMVcoreIRES and pCMVcoreKozak expressed 0.22 +/- 0.18, 0.83 +/- 0.5, and 13 +/- 5 ng core per cell, respectively. Single immunization with highly expressing pCMVcoreKozak induced specific IFN-gamma and IL-2, and weak antibody response. Single immunization with plasmids directing low levels of core expression induced similar levels of cytokines, strong T-cell proliferation (pCMVcoreIRES), and antibodies in titer 103(pCMVcore). Boosting with pCMVcoreKozak induced low antibody response, core-specific T-cell proliferation and IFN-gamma secretion that subsided after the 3rd plasmid injection. The latter also led to a decrease in specific IL-2 secretion. The best was the heterologous pCMVcoreKozak prime/protein boost regiment that generated mixed Th1/Th2-cellular response with core-specific antibodies in titer >or= 3 x 10(3).</p><p><strong>Conclusion: </strong>Thus, administration of highly expressed HCV core gene, as one large dose or repeated injections of smaller doses, may suppress core-specific immune response. Instead, the latter is induced by a heterologous DNA prime/protein boost regiment that circumvents the negative effects of intracellular core expression.</p>","PeriodicalId":12596,"journal":{"name":"Genetic Vaccines and Therapy","volume":"7 ","pages":"7"},"PeriodicalIF":0.0000,"publicationDate":"2009-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1479-0556-7-7","citationCount":"29","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic Vaccines and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/1479-0556-7-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 29

Abstract

Background: Hepatitis C core protein is an attractive target for HCV vaccine aimed to exterminate HCV infected cells. However, although highly immunogenic in natural infection, core appears to have low immunogenicity in experimental settings. We aimed to design an HCV vaccine prototype based on core, and devise immunization regimens that would lead to potent anti-core immune responses which circumvent the immunogenicity limitations earlier observed.

Methods: Plasmids encoding core with no translation initiation signal (pCMVcore); with Kozak sequence (pCMVcoreKozak); and with HCV IRES (pCMVcoreIRES) were designed and expressed in a variety of eukaryotic cells. Polyproteins corresponding to HCV 1b amino acids (aa) 1-98 and 1-173 were expressed in E. coli. C57BL/6 mice were immunized with four 25-microg doses of pCMVcoreKozak, or pCMV (I). BALB/c mice were immunized with 100 microg of either pCMVcore, or pCMVcoreKozak, or pCMVcoreIRES, or empty pCMV (II). Lastly, BALB/c mice were immunized with 20 microg of core aa 1-98 in prime and boost, or with 100 microg of pCMVcoreKozak in prime and 20 microg of core aa 1-98 in boost (III). Antibody response, [3H]-T-incorporation, and cytokine secretion by core/core peptide-stimulated splenocytes were assessed after each immunization.

Results: Plasmids differed in core-expression capacity: mouse fibroblasts transfected with pCMVcore, pCMVcoreIRES and pCMVcoreKozak expressed 0.22 +/- 0.18, 0.83 +/- 0.5, and 13 +/- 5 ng core per cell, respectively. Single immunization with highly expressing pCMVcoreKozak induced specific IFN-gamma and IL-2, and weak antibody response. Single immunization with plasmids directing low levels of core expression induced similar levels of cytokines, strong T-cell proliferation (pCMVcoreIRES), and antibodies in titer 103(pCMVcore). Boosting with pCMVcoreKozak induced low antibody response, core-specific T-cell proliferation and IFN-gamma secretion that subsided after the 3rd plasmid injection. The latter also led to a decrease in specific IL-2 secretion. The best was the heterologous pCMVcoreKozak prime/protein boost regiment that generated mixed Th1/Th2-cellular response with core-specific antibodies in titer >or= 3 x 10(3).

Conclusion: Thus, administration of highly expressed HCV core gene, as one large dose or repeated injections of smaller doses, may suppress core-specific immune response. Instead, the latter is induced by a heterologous DNA prime/protein boost regiment that circumvents the negative effects of intracellular core expression.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
增强HCV核心基因的表达不增强DNA免疫中的核心特异性免疫反应:异源DNA引物、蛋白增强免疫方案的优势。
背景:丙型肝炎核心蛋白是HCV疫苗杀灭HCV感染细胞的一个有吸引力的靶点。然而,尽管在自然感染中具有高度的免疫原性,但在实验环境中似乎具有低免疫原性。我们的目标是设计一种基于core的HCV疫苗原型,并设计免疫方案,从而产生有效的抗core免疫反应,从而绕过先前观察到的免疫原性限制。方法:无翻译起始信号的质粒编码核(pCMVcore);用Kozak序列(pCMVcoreKozak);设计并在多种真核细胞中表达了HCV感染的IRES (pCMVcoreIRES)。大肠杆菌中表达了HCV 1b氨基酸(aa) 1-98和1-173对应的多蛋白。C57BL/6小鼠分别接种4种25 μ g pCMVcoreKozak或pCMV (I)免疫,BALB/c小鼠接种100 μ g pCMVcoreKozak或pCMVcoreKozak或pCMVcoreIRES或空pCMV (II)免疫。最后,BALB/c小鼠接种20 μ g core aa 1-98先导和增强剂,或100 μ g pCMVcoreKozak先导和20 μ g core aa 1-98增强剂(III)免疫。每次免疫后检测核心/核心肽刺激的脾细胞的细胞因子分泌。结果:质粒在核心表达能力上存在差异:转染pCMVcore、pCMVcoreIRES和pCMVcoreKozak的小鼠成纤维细胞每细胞分别表达0.22 +/- 0.18、0.83 +/- 0.5和13 +/- 5 ng核心。高表达pCMVcoreKozak单次免疫诱导特异性ifn - γ和IL-2,抗体反应弱。用质粒引导低水平核心表达的单次免疫诱导相似水平的细胞因子、强t细胞增殖(pCMVcoreIRES)和103滴度抗体(pCMVcore)。pCMVcoreKozak增强诱导低抗体反应,核心特异性t细胞增殖和ifn - γ分泌,在第3次质粒注射后消退。后者也导致特异性IL-2分泌减少。最佳的是异源pCMVcoreKozak引物/蛋白增强团,产生混合Th1/ th2细胞反应,核心特异性抗体滴度>或= 3 × 10(3)。结论:因此,高表达HCV核心基因的一次大剂量或重复小剂量注射可能抑制核心特异性免疫反应。相反,后者是由异源DNA引物/蛋白质促进团诱导的,该团绕过了细胞内核心表达的负面影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Retraction: Structure based sequence analysis & epitope prediction of gp41 HIV1 envelope glycoprotein isolated in Pakistan. DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand? Evaluation of the immune responses induced by four targeted DNA vaccines encoding the juvenile liver fluke antigen, cathepsin B in a mouse model. Targeting wild-type Erythrocyte receptors for Plasmodium falciparum and vivax Merozoites by Zinc Finger Nucleases In- silico: Towards a Genetic Vaccine against Malaria. A brief review on dengue molecular virology, diagnosis, treatment and prevalence in Pakistan.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1